logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Inolimomab for acute Graft versus Host Disease

< Back

Inolimomab for acute Graft versus Host Disease

Drugs

January 2021


Inolimomab is being developed for the treatment of grade II to IV steroid-refractory acute Graft versus Host Disease (aGvHD) in adult patients after allogeneic haematopoietic stem cell transplantation (aHSCT). GvHD is characterised as a frequent complication of bone marrow transplantation and involves a reaction between the donor cells and the recipient’s native tissues, leading to injury of the recipient’s tissues. GvHD occurs in acute and chronic form. The organs most commonly affected in aGvHD are the stomach and the intestines, the skin, and the liver. Up to 50% of aGvHD patients do not respond to initial steroid treatment and are left with few therapeutic options.
Inolimomab, administered intravenously, is an artificially produced antibody that specifically recognises a protein, the CD25 antibody, found on those cells of the immune system that are activated, thereby causing the GvHD. Inolimomab is expected to bind to these cells and stop their multiplication. Cells which are not involved in the GvHD immune reaction and, therefore, not activated at the time of the administration of the product, would be preserved. If licensed, inolimomab would offer an additional treatment option for adult patients with grade II to IV steroid-refractory aGvHD after aHSCT.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Get Alerts